




RealRate

## PHARMACEUTICAL 2020

CymaBay Therapeutics Inc.  
Rank 188 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)



## PHARMACEUTICAL 2020

### CymaBay Therapeutics Inc. Rank 188 of 362

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 321% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -188%, being 114% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	202,923
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,636
Liabilities, Non-Current	1,743
Other Assets	395
Other Compr. Net Income	138
Other Expenses	5,075
Other Liabilities	0
Other Net Income	5,342
Property and Equipment	2,409
Research and Development	83,837
Revenues	0
Selling, General and Administrative Expense	19,238

Output Variable	Value in 1000 USD
Assets	205,727
Liabilities	19,379
Expenses	108,150
Stockholders Equity	186,348
Net Income	-102,808
Comprehensive Net Income	-102,739
Economic Capital Ratio	-188%

